Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kluth, LA; Shariat, SF; Kratzik, C; Tagawa, S; Sonpavde, G; Rieken, M; Scherr, DS; Pummer, K.
The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.
World J Urol. 2014; 32(3):669-676
Doi: 10.1007/s00345-013-1157-5
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pummer Karl
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) may play important roles in prostate cancer (PCa) progression. Specifically, LH expression in PCa tissues has been associated with metastatic disease with a poor prognosis, while FSH has been shown to stimulate prostate cell growth in hormone-refractory PCa cell lines. Gonadotropin-realizing hormone (GnRH) analogues are common agents used for achieving androgen deprivation in the treatment for PCa. GnRH analogues include LH-releasing hormone (LHRH) agonists and GnRH antagonists, both of which exhibit distinct mechanisms of action that may be crucial in terms of their overall clinical efficacy. LHRH agonists are typically used as the primary therapy for most patients and function via a negative-feedback mechanism. This mechanism involves an initial surge in testosterone levels, which may worsen clinical symptoms of PCa. GnRH antagonists provide rapid and consistent hormonal suppression without the initial surge in testosterone levels associated with LHRH agonists, thus representing an important therapeutic alternative for patients with PCa. The concentrations of testosterone and dihydrotestosterone are significantly reduced after treatment with both LHRH agonists and GnRH antagonists. This reduction in testosterone concentrations to castrate levels results in significant, rapid, and consistent reductions in prostatic-specific antigen, a key biomarker for PCa. Evidence suggests that careful maintenance of testosterone levels during androgen deprivation therapy provides a clinical benefit to patients with PCa, emphasizing the need for constant monitoring of testosterone concentrations throughout the course of therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Androgen Antagonists - therapeutic use
- Antineoplastic Agents, Hormonal - therapeutic use
- Gonadotropin-Releasing Hormone - antagonists & inhibitors
- Humans -
- Hypothalamo-Hypophyseal System - drug effects
- Hypothalamo-Hypophyseal System - metabolism
- Male -
- Prostatic Neoplasms - drug therapy
- Prostatic Neoplasms - metabolism
- Find related publications in this database (Keywords)
- Androgen deprivation therapy
- Hypothalamic-pituitary-gonadal axis
- Prostate cancer
- GnRH analogues
- GnRH antagonist
- LHRH agonist